Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Apr 28

PMID 37111325

Authors

Aleksander Kwasny

Adam Wlodarczyk

Damian Ogonowski

Wieslaw Jerzy Cubala

Affiliations

Soon will be listed here.

Abstract

Background: Depression is a debilitating disease with a high socioeconomic burden. Regular antidepressants usually require several weeks to ameliorate symptoms; however, numerous patients do not achieve remission. What is more, sleep disturbances are one of the most common residual symptoms. Ketamine is a novel antidepressant with rapid onset of action with a proven antisuicidal effect. Little is known about its impact on sleep-wake and circadian rhythm alterations. The aim of this systematic review is to research the impact ketamine has on sleep disturbances in depression.

Methods: PubMed, Web of Science, and APA PsycINFO were searched for relevant studies on ketamine's impact on sleep disturbances in depression. Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA2020 methodology was applied. The systematic review protocol was registered in the PROSPERO Registry (CRD42023387897).

Results: Five studies were included in this review. Two studies reported significant improvement in sleep measured by MADRS (Montgomery-Åsberg Depression Rating Scale) and QIDS-SR16 (Quick Inventory of Depressive Symptomatology Self-Report (16-item)) scales after intravenous ketamine and intranasal esketamine administration. One case report showed mitigation of symptoms in PSQI (Pittsburgh Sleep Quality Index) and ISI (Insomnia Severity Index) during 3-month treatment with esketamine. In two studies, sleep was objectively measured by nocturnal EEG (electroencephalography) and showed a decrease in nocturnal wakefulness accompanied by an increase in slow wave (SWS) and rapid eye movement (REM) sleep.

Conclusion: Ketamine reduces the severity of sleep insomnia in depression. Robust data are lacking. More research is needed.

Citing Articles

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.

Reid M, Kettner H, Blanken T, Weiss B, Carhartt-Harris R Curr Psychiatry Rep. 2024; 26(11):659-669.

PMID: 39532819 PMC: 11579049. DOI: 10.1007/s11920-024-01539-8.

Circadian clock dysregulation: a potential mechanism of depression in obstructive sleep apnea patients.

Gabryelska A, Turkiewicz S, Kaczmarski P, Gajewski A, Bialasiewicz P, Strzelecki D Transl Psychiatry. 2024; 14(1):423.

PMID: 39375341 PMC: 11458778. DOI: 10.1038/s41398-024-03134-0.

The association between salivary IL-6 and poor sleep quality assessed using Apple watches in stressed workers in Japan.

Koreki A, Sado M, Mitsukura Y, Tachimori H, Kubota A, Kanamori Y Sci Rep. 2024; 14(1):22620.

PMID: 39349506 PMC: 11442746. DOI: 10.1038/s41598-024-70834-4.

Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.

Kwasny A, Cubala W, Wlodarczyk A, Pastuszak K Pharmacol Rep. 2024; 76(6):1325-1332.

PMID: 39207673 PMC: 11582297. DOI: 10.1007/s43440-024-00641-1.

References

Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W . Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017; 19(9):63. PMC: 5548844. DOI: 10.1007/s11920-017-0816-4. View

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

Liu Y, Lin D, Wu B, Zhou W . Ketamine abuse potential and use disorder. Brain Res Bull. 2016; 126(Pt 1):68-73. DOI: 10.1016/j.brainresbull.2016.05.016. View

Regier D, Kuhl E, Kupfer D . The DSM-5: Classification and criteria changes. World Psychiatry. 2013; 12(2):92-8. PMC: 3683251. DOI: 10.1002/wps.20050. View

Maj M, Stein D, Parker G, Zimmerman M, Fava G, De Hert M . The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020; 19(3):269-293. PMC: 7491646. DOI: 10.1002/wps.20771. View

Borentain S, Williamson D, Turkoz I, Popova V, McCall W, Mathews M . Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials. Neuropsychiatr Dis Treat. 2021; 17:3459-3470. PMC: 8646953. DOI: 10.2147/NDT.S339090. View

Wilkowska A, Wiglusz M, Galuszko-Wegielnik M, Wlodarczyk A, Cubala W . Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression. Front Psychiatry. 2021; 12:704330. PMC: 8558390. DOI: 10.3389/fpsyt.2021.704330. View

Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D . Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000; 47(4):351-4. DOI: 10.1016/s0006-3223(99)00230-9. View

Hirota K, Lambert D . Ketamine; history and role in anesthetic pharmacology. Neuropharmacology. 2022; 216:109171. DOI: 10.1016/j.neuropharm.2022.109171. View

10.

Stultz D, Stanley N, Gills T, Osburn S, Burns T, Moomaw S . Three Months of Treatment With Esketamine: Effects on Depression, Insomnia, and Weight. Prim Care Companion CNS Disord. 2020; 22(4). DOI: 10.4088/PCC.19l02555. View

11.

Hashimoto K . Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci. 2019; 73(10):613-627. PMC: 6851782. DOI: 10.1111/pcn.12902. View

12.

Rodrigues N, McIntyre R, Lipsitz O, Cha D, Cao B, Lee Y . Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. J Sleep Res. 2021; 31(1):e13400. DOI: 10.1111/jsr.13400. View

13.

Duncan Jr W, Ballard E, Zarate C . Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood. Handb Exp Pharmacol. 2017; 253:337-358. PMC: 5866161. DOI: 10.1007/164_2017_51. View

14.

Duncan Jr W, Slonena E, Hejazi N, Brutsche N, Yu K, Park L . Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties. Biol Psychiatry. 2017; 82(5):361-369. PMC: 5546993. DOI: 10.1016/j.biopsych.2017.03.011. View

15.

Gaynes B, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J . Defining treatment-resistant depression. Depress Anxiety. 2019; 37(2):134-145. DOI: 10.1002/da.22968. View

16.

Ng C, Kato T, Han C, Wang G, Trivedi M, Ramesh V . Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2018; 245:626-636. DOI: 10.1016/j.jad.2018.11.038. View

17.

Breitstein J, Penix B, Roth B, Baxter T, Mysliwiec V . Intensive sleep deprivation and cognitive behavioral therapy for pharmacotherapy refractory insomnia in a hospitalized patient. J Clin Sleep Med. 2014; 10(6):689-90. PMC: 4031412. DOI: 10.5664/jcsm.3804. View

18.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

19.

McClintock S, Husain M, Wisniewski S, Nierenberg A, Stewart J, Trivedi M . Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2):180-6. PMC: 3677201. DOI: 10.1097/JCP.0b013e31820ebd2c. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View